NCCN Guidelines® Insights: Multiple myeloma, version 3.2018: Featured updates to the NCCN guidelines Journal Article
| Authors: | Kumar, S. K.; Callander, N. S.; Alsina, M.; Atanackovic, D.; Biermann, J. S.; Castillo, J.; Chandler, J. C.; Costello, C.; Faiman, M.; Fung, H. C.; Godby, K.; Hofmeister, C.; Holmberg, L.; Holstein, S.; Huff, C. A.; Kang, Y.; Kassim, A.; Liedtke, M.; Malek, E.; Martin, T.; Neppalli, V. T.; Omel, J.; Raje, N.; Singhal, S.; Somlo, G.; Stockerl-Goldstein, K.; Weber, D.; Yahalom, J.; Kumar, R.; Shead, D. A. |
| Article Title: | NCCN Guidelines® Insights: Multiple myeloma, version 3.2018: Featured updates to the NCCN guidelines |
| Abstract: | The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, evaluation, treatment, including supportive-care, and follow-up for patients with myeloma. These NCCN Guidelines Insights highlight the important updates/changes specific to the myeloma therapy options in the 2018 version of the NCCN Guidelines. © 2018 JNCCN-Journal of the National Comprehensive Cancer Network. |
| Keywords: | treatment response; lenalidomide; thalidomide; review; cisplatin; doxorubicin; follow up; bortezomib; multiple myeloma; etoposide; maintenance therapy; bendamustine; cyclophosphamide; dexamethasone; practice guideline; patient care; panobinostat; carfilzomib; phase 2 clinical trial (topic); phase 3 clinical trial (topic); multicenter study (topic); pomalidomide; human; elotuzumab; ixazomib; daratumumab |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 16 |
| Issue: | 1 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2018-01-01 |
| Start Page: | 11 |
| End Page: | 20 |
| Language: | English |
| DOI: | 10.6004/jnccn.2018.0002 |
| PROVIDER: | scopus |
| PUBMED: | 29295877 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 February 2018 -- Source: Scopus |
